{"altmetric_id":4147032,"counts":{"readers":{"mendeley":6,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["BatuBiologics"],"posts_count":1}},"selected_quotes":["angiotensin inhibitors in renal cancer patients after surgery survival 96.8 % vs 89.8 % (P = 0.019)"],"citation":{"altmetric_jid":"4f6fa60b3cf058f610006a31","authors":["Miyajima A","Yazawa S","Kosaka T","Tanaka N","Shirotake S","Mizuno R","Kikuchi E","Oya M"],"doi":"10.1245\/s10434-015-4436-0","first_seen_on":"2015-06-13T16:11:22+00:00","issns":["1068-9265"],"journal":"Annals of Surgical Oncology","last_mentioned_on":1434211809,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25691280"],"pmid":"25691280","pubdate":"2015-02-18T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["neoplasms","generalsurgery"],"title":"Prognostic Impact of Renin-Angiotensin System Blockade on Renal Cell Carcinoma After Surgery.","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/prognostic-impact-reninangiotensin-system-blockade-renal-cell-carcinoma-after-surgery"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":5223626,"mean":6.1581687165544,"rank":4348280,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":5223626,"percentile":1},"similar_age_3m":{"total_number_of_other_articles":178145,"mean":8.6376836604097,"rank":145039,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":178145,"percentile":1},"this_journal":{"total_number_of_other_articles":1444,"mean":3.6294372834373,"rank":1119,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":1444,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":75,"mean":2.7882432432432,"rank":55,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":75,"percentile":1}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}},"mendeley":{"by_status":{"Researcher":1,"Student  > Ph. D. Student":1,"Other":2,"Student  > Master":1,"Student  > Bachelor":1},"by_discipline":{"Medicine and Dentistry":2,"Agricultural and Biological Sciences":2,"Biochemistry, Genetics and Molecular Biology":1,"Arts and Humanities":1}}},"geo":{"twitter":{"US":1}}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/BatuBiologics\/status\/609754638955364354","license":"datasift","citation_ids":[4147032],"posted_on":"2015-06-13T16:10:09+00:00","author":{"name":"Batu Biologics","url":"http:\/\/Www.batubiologics.com","image":"https:\/\/pbs.twimg.com\/profile_images\/484482344292581376\/7dQJNzF5_normal.jpeg","description":"Immuno-oncology firm Batu Biologics is developing universal donor therapies targeting multiple pathways to enhance efficacy & specificity of cancer treatments","id_on_source":"BatuBiologics","tweeter_id":"2600575544","geo":{"lt":32.71533,"ln":-117.15726,"country":"US"},"followers":474},"tweet_id":"609754638955364354"}]}}